310 related articles for article (PubMed ID: 24425047)
1. Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.
Sikora MJ; Cooper KL; Bahreini A; Luthra S; Wang G; Chandran UR; Davidson NE; Dabbs DJ; Welm AL; Oesterreich S
Cancer Res; 2014 Mar; 74(5):1463-74. PubMed ID: 24425047
[TBL] [Abstract][Full Text] [Related]
2. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
[TBL] [Abstract][Full Text] [Related]
3. Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast.
Sottnik JL; Bordeaux EK; Mehrotra S; Ferrara SE; Goodspeed AE; Costello JC; Sikora MJ
Mol Cancer Res; 2021 Aug; 19(8):1270-1282. PubMed ID: 33947745
[TBL] [Abstract][Full Text] [Related]
4. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
Du T; Sikora MJ; Levine KM; Tasdemir N; Riggins RB; Wendell SG; Van Houten B; Oesterreich S
Breast Cancer Res; 2018 Sep; 20(1):106. PubMed ID: 30180878
[TBL] [Abstract][Full Text] [Related]
5. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
Nardone A; Qiu X; Spisak S; Nagy Z; Feiglin A; Feit A; Cohen Feit G; Xie Y; Font-Tello A; Guarducci C; Hermida-Prado F; Syamala S; Lim K; Munoz Gomez M; Pun M; Cornwell M; Liu W; Ors A; Mohammed H; Cejas P; Brock JB; Freedman ML; Winer EP; Fu X; Schiff R; Long HW; Metzger Filho O; Jeselsohn R
Cancer Res; 2022 Oct; 82(20):3673-3686. PubMed ID: 35950920
[TBL] [Abstract][Full Text] [Related]
6. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma.
Bossart EA; Tasdemir N; Sikora MJ; Bahreini A; Levine KM; Chen J; Basudan A; Jacobsen BM; Burns TF; Oesterreich S
Breast Cancer Res Treat; 2019 Jun; 175(2):327-337. PubMed ID: 30798422
[TBL] [Abstract][Full Text] [Related]
7. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ
Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
9. A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer.
Blawski R; Toska E
Cancer Res; 2022 Oct; 82(20):3668-3670. PubMed ID: 36245246
[TBL] [Abstract][Full Text] [Related]
10. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
11. BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.
Walsh L; Haley KE; Moran B; Mooney B; Tarrant F; Madden SF; Di Grande A; Fan Y; Das S; Rueda OM; Dowling CM; Varešlija D; Chin SF; Linn S; Young LS; Jirström K; Crown JP; Bernards R; Caldas C; Gallagher WM; O'Connor DP; Ní Chonghaile T
Clin Cancer Res; 2019 Dec; 25(23):7139-7150. PubMed ID: 31409615
[TBL] [Abstract][Full Text] [Related]
12. FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression.
Lv Q; Guan S; Zhu M; Huang H; Wu J; Dai X
Technol Cancer Res Treat; 2021; 20():15330338211004935. PubMed ID: 33783288
[TBL] [Abstract][Full Text] [Related]
13. Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.
Stires H; Heckler MM; Fu X; Li Z; Grasso CS; Quist MJ; Lewis JA; Klimach U; Zwart A; Mahajan A; Győrffy B; Cavalli LR; Riggins RB
Mol Cell Endocrinol; 2018 Aug; 471():105-117. PubMed ID: 28935545
[TBL] [Abstract][Full Text] [Related]
14. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer.
Riggins RB; Lan JP; Zhu Y; Klimach U; Zwart A; Cavalli LR; Haddad BR; Chen L; Gong T; Xuan J; Ethier SP; Clarke R
Cancer Res; 2008 Nov; 68(21):8908-17. PubMed ID: 18974135
[TBL] [Abstract][Full Text] [Related]
15. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
16. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
17. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
18. Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.
Sreekumar S; Levine KM; Sikora MJ; Chen J; Tasdemir N; Carter D; Dabbs DJ; Meier C; Basudan A; Boone D; McAuliffe PF; Jankowitz RC; Lee AV; Atkinson JM; Oesterreich S
Endocrinology; 2020 Sep; 161(9):. PubMed ID: 32609836
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
20. Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features.
Jambal P; Badtke MM; Harrell JC; Borges VF; Post MD; Sollender GE; Spillman MA; Horwitz KB; Jacobsen BM
Breast Cancer Res Treat; 2013 Jan; 137(2):431-48. PubMed ID: 23247610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]